Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viromed Medical AGFRA:VME -0.65%22 EV-to-EBIT is -303.76 as of Aug. 08, 2026. GuruFocus rates FRA:VME with a GF Score™ of 22/100. The stock has 5 warning signs investors should review. Among 469 Medical Devices & Instruments companies, Viromed Medical AG ranks worse than 213219.4% on this metric.
The historical rank and industry rank for Viromed Medical AG's EV-to-EBIT or its related term are showing as below:
FRA:VME'
s EV-to-EBIT Range Over the Past 10 Years
Min: -311.72 Med: -26.32 Max: -9.96
Current: -303.76
During the past 5 years, the highest EV-to-EBIT of Viromed Medical AG was -9.96. The lowest was -311.72. And the median was -26.32.
FRA:VME's EV-to-EBIT is ranked worse than 100% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 19.13
vs FRA:VME: -303.76
Viromed Medical AG (FRA:VME) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Viromed Medical AG's Enterprise Value for the quarter that ended in Dec. 2025 was €79.55 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Viromed Medical AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viromed Medical AG EV-to-EBIT Related Terms
Viromed Medical AG EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Viromed Medical AG's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Viromed Medical AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viromed Medical AG EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Viromed Medical AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Viromed Medical AG's EV-to-EBIT falls into.
Viromed Medical AG's current Enterprise Value is €162.21 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Viromed Medical AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viromed Medical AG (FRA:VME) has a EV-to-EBIT of -303.76 as of Aug. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Viromed Medical AG and its competitors. According to the industry distribution chart, Viromed Medical AG ranks #999999 out of 469 companies in the Medical Devices & Instruments industry.
Is Viromed Medical AG's EV-to-EBIT too high?
Viromed Medical AG's current EV-to-EBIT is -303.76. Based on the distribution chart, Viromed Medical AG ranks #999999 out of 469 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Viromed Medical AG has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Viromed Medical AG's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Viromed Medical AG ranks #999999 out of 469 companies for EV-to-EBIT. This places Viromed Medical AG in the lower half of its industry. The industry median EV-to-EBIT is 19.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.13, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Viromed Medical AG and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viromed Medical AG's current EV-to-EBIT is -303.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viromed Medical AG stock overvalued right now?
Viromed Medical AG (FRA:VME) has a current EV-to-EBIT of -303.76. The current EV-to-EBIT is -303.76. Viromed Medical AG's overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Viromed Medical AG (FRA:VME), the current EV-to-EBIT is -303.76 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Viromed Medical AG is a medical technology company. It focuses on using cold plasma technology to develop medical solutions that protect people from viruses, bacteria, and multi-resistant germs. Viromed's product offerings include ViroCAP, a medical device based on cold plasma technology for treating wounds; ViroCAP derma-podo, a medical device that uses cold atmospheric plasma therapy for skin and foot care; and a Raumluftentkeimer. The company covers the entire value chain from research and development to production, logistics, marketing, and sales of its products.
22GF Score
Get the complete analysis for FRA:VME
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VME has been successfully added to your 
